Replies to post #440373 on NorthWest Biotherapeutics Inc (NWBO)

[Bob_LobLaw]

I think we all believe the company is going to deliver very successful data which will be well received and the market will begin to recognize the value of NWBO and the DCVax platform.... at some point. The stock price today technically does not matter to those who are not selling. I believe LP and LG say to those who are selling now... F them. But this sandbag game does keep the price low. Does a low price benefit anyone? me wonders

[Extremist223]

You're speaking like the FDA has accepted revised endpoints just because the company data locked... You don't know that they or Health Canada have accepted the endpoints. and I also disagree, they are changing the end points last minute. At the very least, some sort of discussion for shorts should be had. Do you expect shorts to lose money because of that if they would've been originally correct with the old endpoints?

[HappyLibrarian]

Stupid or not it is consistent NWBO's corporate culture to keep shareholders in the dark as much as those laws and regulations which are actually enforceable allow.

Even the use of Cognate and now Advent is a way where core activities are outsourced to a privately held company that management controls allowing them to have their cake and eat it too as far as being a public company and yet leaving a lot hidden because it is being done by a private firm.

Even back when NWBO was actively courting shareholders (the Red Chip Report and Fox Business era) they were always slippery in their use of language and as time has passed they have gotten to such an extreme that even very broad and generous expressions like 'coming months' cannot be relied upon at all.

If NWBO was a privately held company, this would be fine. If clincaltrials.gov was not a government website that patients, doctors and yes investors rely upon for accurate information then this would be fine.

While this is not fine, it will continue to go on and with no end in sight. At this point, it is doubtful that even stellar TLD that gets an article referenced on the front page of the best journal is going to magically fix this company's behavior. It is just too deeply ingrained.

[It Is What It Is]

OK, thank you for clarifying. I misunderstood and thought you were saying NWBO should pay attention and follow AVXL's lead. My apologies. I 100-percent agree that NWBO should have updated the trial registry long ago.

[dennisdave]

100% agree

I am saying it was stupid of AVXL and NWBO to wait to make the changes on the u.s. clinical trial registry.

NWBO should have made the change a year and a half ago when they changed endpoints.

I bet it was Les that has stood up against making the change earlier. NWBO needs to put their egos aside and update the registry.

(NWBO’s changes to endpoints were not last second, but they still have not changed the U.S. clinical trial registry, which bears will undoubtedly twist.)